MA27443A1 - Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) - Google Patents

Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Info

Publication number
MA27443A1
MA27443A1 MA28157A MA28157A MA27443A1 MA 27443 A1 MA27443 A1 MA 27443A1 MA 28157 A MA28157 A MA 28157A MA 28157 A MA28157 A MA 28157A MA 27443 A1 MA27443 A1 MA 27443A1
Authority
MA
Morocco
Prior art keywords
tgf
thiazoles
transforming growth
inhibitors
oxazoles
Prior art date
Application number
MA28157A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27443A1 publication Critical patent/MA27443A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REVENDICATION DE PRIORITES US 18 Septembre 2002 60/412,120 US 16 Mai 2003 60/471,265 US 2 Juillet 2003 60/484,581 Voir en annexe le titre de l'invention et le texte de l'abrégé Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (TGF) Des oxazoles et thiazoles nouveaux, y compris leurs dérivés, des intermédiaires pour leur préparation, des compositions pharmaceutiques les contenant, et leur utilisation en médecine sont décrits. Les composés de la présente invention sont de puissants inhibiteurs de la voie de transmission de signal du facteur de croissance transformant ("TGF")-(bêta). Ils sont utiles dans le traitement de divers états pathologiques en rapport avec le TGF, comprenant, par exemple, le cancer et des maladies fibrotiques.
MA28157A 2002-09-18 2005-03-18 Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) MA27443A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
MA27443A1 true MA27443A1 (fr) 2005-07-01

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28157A MA27443A1 (fr) 2002-09-18 2005-03-18 Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Country Status (28)

Country Link
US (1) US7273936B2 (fr)
EP (1) EP1542994B1 (fr)
JP (1) JP4518956B2 (fr)
KR (1) KR20050057415A (fr)
CN (1) CN1681810A (fr)
AP (1) AP2005003261A0 (fr)
AR (1) AR041273A1 (fr)
AT (1) ATE430147T1 (fr)
AU (1) AU2003256003A1 (fr)
BR (1) BR0314383A (fr)
CA (1) CA2499429C (fr)
CO (1) CO5550473A2 (fr)
CR (1) CR7743A (fr)
DE (1) DE60327443D1 (fr)
EA (1) EA200500354A1 (fr)
ES (1) ES2323421T3 (fr)
HR (1) HRP20050250A2 (fr)
IS (1) IS7711A (fr)
MA (1) MA27443A1 (fr)
MX (1) MXPA05002332A (fr)
NO (1) NO20051838L (fr)
OA (1) OA12926A (fr)
PA (1) PA8582701A1 (fr)
PE (1) PE20040987A1 (fr)
PL (1) PL375975A1 (fr)
TW (1) TW200413362A (fr)
UY (1) UY27978A1 (fr)
WO (1) WO2004026863A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
KR20050057392A (ko) * 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
OA12929A (en) * 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
RU2007109073A (ru) * 2004-08-13 2008-09-20 Дженентек, Инк. (Us) Ингибиторы для атф-зависимого фермента на основе тиазола
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP2289510A1 (fr) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
EP2269610A3 (fr) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
EP1799667B1 (fr) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2007070866A2 (fr) * 2005-12-16 2007-06-21 Alcon, Inc. Controle de la pression intraoculaire a l'aide d'agents de modulation d'alk5
EP2154965A4 (fr) * 2007-05-29 2011-08-17 Glaxosmithkline Llc Dérivés de naphtyridine en tant qu'inhibiteurs de p13 kinase
WO2009111502A2 (fr) 2008-03-03 2009-09-11 University Of Notre Dame Du Lac Composés anticancéreux, synthèse de ceux-ci, et procédés utilisant ceux-ci
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
EP3515446B1 (fr) 2016-09-19 2023-12-20 Novartis AG Combinaisons thérapeutiques comprenant un inhibiteur de raf et un inhibiteur d'erk
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
CA3066423A1 (fr) * 2017-06-14 2018-12-20 Trevena, Inc. Composes pour moduler l'activite de s1p1 et leurs procedes d'utilisation
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
AR037061A1 (es) 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20040039198A1 (en) 2000-11-16 2004-02-26 Bender Paul E. Compounds
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
EP1354603A1 (fr) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Co-prescriptions
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
US20040077697A1 (en) 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
EP1402900A1 (fr) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Compositions medicinales
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003260345A1 (en) 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
OA12929A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
KR20050057392A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
OA12927A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors.

Also Published As

Publication number Publication date
BR0314383A (pt) 2005-07-19
CN1681810A (zh) 2005-10-12
KR20050057415A (ko) 2005-06-16
AP2005003261A0 (en) 2005-03-31
PA8582701A1 (es) 2004-04-23
US7273936B2 (en) 2007-09-25
MXPA05002332A (es) 2005-06-08
OA12926A (en) 2006-10-13
JP2006502235A (ja) 2006-01-19
WO2004026863A8 (fr) 2005-04-21
UY27978A1 (es) 2004-04-30
EA200500354A1 (ru) 2005-10-27
ATE430147T1 (de) 2009-05-15
TW200413362A (en) 2004-08-01
IS7711A (is) 2005-02-24
NO20051838L (no) 2005-04-15
HRP20050250A2 (en) 2005-10-31
CA2499429C (fr) 2010-09-21
CR7743A (es) 2005-06-15
AR041273A1 (es) 2005-05-11
CO5550473A2 (es) 2005-08-31
AU2003256003A1 (en) 2004-04-08
EP1542994B1 (fr) 2009-04-29
US20040110797A1 (en) 2004-06-10
DE60327443D1 (de) 2009-06-10
PE20040987A1 (es) 2004-12-27
PL375975A1 (en) 2005-12-12
WO2004026863A1 (fr) 2004-04-01
CA2499429A1 (fr) 2004-04-01
EP1542994A1 (fr) 2005-06-22
JP4518956B2 (ja) 2010-08-04
ES2323421T3 (es) 2009-07-15

Similar Documents

Publication Publication Date Title
MA27441A1 (fr) Composes d'imidazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27440A1 (fr) Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)
MA27442A1 (fr) Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27444A1 (fr) Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
NZ542622A (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA27156A1 (fr) NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI
MXPA05009245A (es) Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
AP1408A (en) Phenyl yanthine derivatives.
MA30514B1 (fr) Nouveaux composes.
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA28747B1 (fr) Dérivés de pyridine
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
FR2716883B1 (fr) Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
SE9903894D0 (sv) Novel compounds